Ulrike Dijkman

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Leticia Toledo‐Sherman, Michael E. Prime, Ladislav Mrzljak et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Neurodegenerative Diseases +15

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease

Vahri Beaumont, Ladislav Mrzljak, Ulrike Dijkman et al. · Experimental Neurology · 2016 · 55 citations

Electrophysiological Alterations, Molecular Physiology, Molecular Biology +6

Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat

Matthew Fell, Gunnar Flik, Ulrike Dijkman et al. · Neuropharmacology · 2015 · 17 citations

Neurophysiology, Medicine, Synaptic Transmission +11

The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington’s Disease

Vahri Beaumont, Larry Park, Arash Rassoulpour et al. · PLoS Currents · 2014 · 11 citations · Full text

Neurodegenerative Diseases, Huntington ’, Medicine +14